Company contact point

Medical Information at Roche Products (Ireland) Limited by telephone (01 4690700) or email (Ireland.druginfo@roche.com).

Please read this material along with the Package Leaflet supplied with this medicine or also available on www.medicines.ie or www.ema.europa.eu before taking this medicine.

Reporting of side effects

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects, talk to your doctor, pharmacist or nurse. You can report side effects directly via HPRA Pharmacovigilance, Website: www.hpra.ie

By reporting side effects, you can help provide more information on the safety of this medicine.

Side effects can also be reported to
The Drug Surveillance Centre,
Roche Products (Ireland) Limited,
3030 Lake Drive, Citywest Business Campus,
Dublin 24, D24 KX6Y, Ireland
Telephone: (01) 4690700
Email: ireland.drug_surveillance_centre@roche.com

Further Information

Talk to your doctor, nurse or pharmacist if you have any questions or concerns.

IE Version 2.0.2
M-IE-00001502
Date of Preparation: April 2026
Date of HPRA Approval: April 2026

FOR USE IN IRELAND

Important Safety Information for Patients receiving Lunsumio▼ (mosunetuzumab)

Patient Card

This card was developed by Roche Products (Ireland) Limited to fulfil the conditions of the marketing authorisation and has been approved by the HPRA.

- Please carry this card with you at all times while you are receiving Lunsumio (mosunetuzumab).
- Show this card to any healthcare professional involved in your care.

Information for the Patient/Caregiver

Contact your doctor or get emergency help **right away** if you have **any** of these symptoms associated with:

Cytokine Release Syndrome (CRS):
- Fever (38°C or higher)
- Fast or irregular heartbeat
- Chills or shaking chills
- Confusion
- Feeling very tired or weakness
- Difficulty breathing
- Dizziness or light-headedness
- Fainting
- Blurred vision
- Cold or pale clammy skin
- Headache

Immune effector cell-associated neurotoxicity syndrome (ICANS):
- Confusion or disorientation
- Hallucinations (seeing, hearing or feeling things that are not there)
- Seizures
- Problems with memory
- Problems with language (difficulty with speech or change in speech)
- Problems with judgement (change in thinking)
- Not being able to concentrate (difficulty staying awake)

Information for the Treating Doctor

This patient has received Lunsumio (mosunetuzumab) **– which may cause Cytokine Release Syndrome (CRS) and/or Immune effector cell-associated neurotoxicity syndrome (ICANS).**

- Evaluate the patient immediately and treat symptoms.
- If CRS or ICANS is suspected, please refer to section 4.2 of the SmPC for comprehensive instructions on clinical management.

- **Contact the prescribing doctor** as soon as possible – they may need to modify the next infusion of Lunsumio (mosunetuzumab).

Contact Information

Patient's name:

Prescribing Doctor's name:

Prescribing Doctor's phone number:

Date of Lunsumio initiation: